Aejaz Ul Haq, MD
Pulmonary Disease · Ocean Springs, MSNPI 1649652595
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (35.6%), travel and lodging and education — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Intuitive Surgical at 37.9% of the total. Reporting peaked in 2024 at $5,209 and has fallen 93.8% since, to $323 in 2025.
Across 144 payments — averaging $60.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- Pulmonx Corporation$1K
- Johnson & Johnson$1K
- Boehringer Ingelheim$333
- AbbVie$313
- AstraZeneca$293
- plus $2K from 26 others
What the payments were for
- Travel & lodging$3,05635%
- Food & beverage$3,12436%
- Education$2,59930%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 5 | $3,330 |
| Pulmonx Corporation | 6 | $1,361 |
| Johnson & Johnson | 7 | $1,233 |
| Boehringer Ingelheim | 15 | $333 |
| AbbVie | 13 | $313 |
| AstraZeneca(2 entities) | 11 | $293 |
| GSK | 18 | $280 |
| United Therapeutics Corporation | 9 | $267 |
| Actelion Pharmaceuticals US, Inc. | 5 | $180 |
| Merck | 8 | $129 |
| Viatris Specialty LLC | 1 | $125 |
| Verona Pharma, Inc. | 1 | $123 |
| Grifols USA, LLC | 5 | $116 |
| Insmed, Inc. | 1 | $105 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $96 |
| Electromed, Inc. | 13 | $80 |
| Bayer | 4 | $70 |
| Sanofi | 3 | $52 |
| La Jolla Pharmaceutical Company | 2 | $35 |
| Portola Pharmaceuticals, LLC | 1 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $24 |
| Inogen, Inc. | 1 | $24 |
| Novartis | 1 | $23 |
| Genentech USA, Inc. | 1 | $21 |
| Chiesi USA, Inc. | 1 | $19 |
| ANI Pharmaceuticals, Inc. | 1 | $19 |
| Mallinckrodt Hospital Products Inc. | 1 | $19 |
| Baxter Healthcare | 1 | $18 |
| Philips North America LLC | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Mallinckrodt Enterprises LLC | 1 | $13 |
| Mylan Specialty L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,242
- ZEPHYR ENDOBRONCHIAL VALVE$1,233
- Monarch Platform$1,195
- Yupelri$125
- Ohtuvayre$123
- FASENRA$122
- Arikayce$105
How this compares
$8,779 in reported general payments places this provider in the 60th percentile of 101 pulmonary disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 13 | $333,758 |
| OpsumitMacitentan | 12 | $151,068 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $45,591 |
| EliquisApixaban | 23 | $12,917 |
| Wixela InhubFluticasone Propion/Salmeterol | 11 | $2,393 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 48 | $1,321 |
| Roflumilast | 13 | $900 |
| Ventolin HfaAlbuterol Sulfate | 12 | $623 |
| Azithromycin | 11 | $328 |
| Montelukast Sodium | 26 | $82 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit | $180 | $151,06812 claims |
| GSKTrelegy Ellipta | $280 | $45,59152 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 101 pulmonary disease providers in Mississippi.
Other pulmonary disease in Ocean Springs
- Sardar BabarOcean Springs$21K
- Jerrod TaylorOcean Springs$11K
- Dipti BaralOcean Springs$11K
- Subhas SitaulaOcean Springs$10K
- Syed Abdullah WaheedOcean Springs$8K
- Bishal GyawaliOcean Springs$7K
- William FrazierCanton$809K
- Demondes HaynesJackson$809K
- Bobby TullosGulfport$276K
- Michal SenitkoJackson$185K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.